Back
Biomerica, Inc. 10K Form
Sell
28
BMRA
Biomerica, Inc.
Last Price:
$2.38
Seasonality Move:
8.98%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-10-12 | 10Q | BMRA/Biomerica, Inc. Quarterly |
| 2023-04-14 | 10Q | BMRA/Biomerica, Inc. Quarterly |
| 2023-01-13 | 10Q | BMRA/Biomerica, Inc. Quarterly |
| 2022-10-13 | 10Q | BMRA/Biomerica, Inc. Quarterly |
| 2022-04-14 | 10Q | BMRA/Biomerica, Inc. Quarterly |
| 2022-01-12 | 10Q | BMRA/Biomerica, Inc. Quarterly |
Receive BMRA News And Ratings
See the #1 stock for the next 7 days that we like better than BMRA
BMRA Financial Statistics
Sales & Book Value
| Annual Sales: | $5.3M |
|---|---|
| Cash Flow: | $-268K |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.83 |
| Price / Book: | 1.17 |
Profitability
| EPS (TTM): | -1.53450 |
|---|---|
| Net Income (TTM): | $-3.7M |
| Gross Margin: | $498K |
| Return on Equity: | -72.37% |
| Return on Assets: | -51.74% |
Biomerica, Inc. Earnings Forecast
Key Biomerica, Inc. Financial Ratios
-
The Gross Profit Margin over the past 42 years for BMRA is 9.38%.
-
The Selling, General & Administrative Expenses for BMRA have been equal to 86.84% of Gross Profit Margin.
-
The Research & Development expenses have been 19.26% of Revenue.
-
The Net Earning history of BMRA is -93.64% of Total Revenues.
-
Per Share Earnings over the last 42 years have been positive in 21 years.
Biomerica, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Health Care Equipment & Supplies |
| Sector: | Health Care |
| Current Symbol: | BMRA |
| CUSIP: | 09061H |
| Website: | biomerica.com |
Debt
| Debt-to-Equity Ratio: | 0.07 |
|---|---|
| Current Ratio: | 3.48 |
| Quick Ratio: | 2.55 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
BMRA Technical Analysis vs Fundamental Analysis
Sell
28
Biomerica, Inc. (BMRA)
is a Sell
Is Biomerica, Inc. a Buy or a Sell?
-
Biomerica, Inc. stock is rated a SellThe current Biomerica, Inc. [BMRA] share price is $2.37. The Score for BMRA is 28, which is 44% below its historic median score of 50, and infers higher risk than normal.